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stellate cell morphologyAtherosclerosis development is associated with morphological changes to intimal cells, leading to a stellate cell
phenotype. In this study, we aimed to determine whether and how key pro-atherogenic cytokines present in
atherosclerotic plaques (IL-1β, TNFα and IFNγ) could induce this phenotype, as these molecules are known to
trigger the transdifferentiation of vascular smooth muscle cells (VSMCs). We found that, IL-1β was the only
major inﬂammatory mediator tested capable of inducing a stellate morphology in VSMCs. This ﬁnding was con-
ﬁrmed by staining for F-actin and vinculin at focal adhesions, as these twomarkers were disrupted only by IL-1β.
We then investigated the possible association of this IL-1β-dependent change inmorphologywith an increase in
intracellular cAMP concentration ([cAMP]), using the FRET-based biosensor for cAMP TEpacVV. Experiments in
the presence of IL-1β or medium conditioned by IL-1β-treated VSMCs and pharmacological tools demonstrated
that the long-term increase in intracellular cAMP concentration was induced by the secretion of an autocrine/
paracrine mediator, prostaglandin E2 (PGE2), acting through the EP4 receptor. Finally, by knocking down the
expression of the regulatory subunit PKAR1α, thereby reproducing the effects of IL-1β and PGE2 on VSMCs, we
demonstrated the contribution of PKA activity to the observed behavior of VSMCs.
© 2015 Elsevier B.V. All rights reserved.lic monophosphate; 8-pCPT-O-
e-3′, 5′-cyclic monophosphate
sine monophosphate; CCL3 or
, chemokine (C–Cmotif) ligand
yan ﬂuorescent protein; COX-2,
–Cmotif) ligand 1; CXCL1, che-
Cmotif) ligand 10; CXCL2, che-
–X–C motif) ligand 3; CXCL5,
idino-2-phenylindole; DMEM,
proteins directly activated by
forskolin; GM-CSF, granulocyte
methylxanthine; IFNγ, interfer-
ow-density lipoproteins; PBS,
rotein kinase A; PTGES1, prosta-
reaction; Rap, Ras-related pro-
-cAMPS, 8-bromoadenosine-3′,
smooth muscle-myosin heavy
ted phospholipase A type IIa;
ween turquoise (T) and venus-
lar endothelial growth factor;
ent protein
me étage, 75005 Paris, France.1. Introduction
Atherosclerosis is the pathological process underlying most cardio-
vascular diseases, including acute coronary syndrome, peripheral artery
disease and ischemic stroke. It is characterized by chronic inﬂammation
of the arterial wall at sites of blood ﬂow disturbance, leading to the
formation of atherosclerotic plaques [1]. Atherosclerosis is promoted
by hypercholesterolemia, which favors the inﬁltration of cholesterol-
containing LDL into the intima of the vessels [2], where it may be
oxidized. Parietal monocytes, which differentiate into macrophages
[3] and vascular smooth muscle cells (VSMCs), which have a
macrophage-like phenotype, take up and destroy oxidized LDLs via
their scavenger receptors. They then become foam cells, and acquire
the ability to secrete several different cytokines, including tumor necro-
sis factor α (TNFα) and interleukin-1β (IL-1β) [4]. Other inﬂammatory
cells, including natural killer cells and lymphocytes, also participate in
chronic inﬂammation by releasing interferon γ (IFNγ), [5]. The
secretion of these compounds contributes to the expansion of athero-
sclerotic lesions, notably by inducing medial VSMCs to undergo
transdifferentiation, modifying their phenotype.
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tiated/contractile phenotype of VSMCs [6–8]. Disruption, defects of
actin cytoskeleton protein smooth muscle 22 alpha (SM22 alpha) are
associated with pro-inﬂammatory and chondrogenic changes to the
VSMC phenotype, aggravating vascular inﬂammation and pathological
remodeling [9,10]. The transdifferentiated VSMCs also acquire new cel-
lular functions, including roles in migration and proliferation, and these
functions are regulated by dynamic actin microﬁlament rearrange-
ments that may result in changes to cell morphology [11–13]. Athero-
sclerosis development is thus associated with morphological changes
to the intimal VSMCs, mostly resulting in the adoption of a stellate
shape due to the loss of focal adhesions and the disassembly of actin
stress ﬁbers. There are very few if any stellate cells in healthy human
aortas, but the number of these cells steadily increases as fatty streaks
gradually develop into advanced atherosclerotic plaques [14]. The role
of VSMCs in atherogenesis may have been largely underestimated, be-
cause the markers used to identify these cells may not be appropriate
[15]. Stellate VSMCs were ﬁrst detected in human aortas, by electron
microscopy, in 1986 [14]. This phenotype iswell known in hepaticﬁbro-
sis [16], but little is known about the role of stellate VSMCs in athero-
sclerosis and the potential mediators triggering the change in
phenotype from contractile to stellate cells.
We show here that IL-1β was the only inﬂammatory mediator of
those tested (IL-1β, TNFα and IFNγ, all of which are present in
plaques) able to trigger the phenotypic transition from contractile to
stellate cells in VSMCs. Early studies described an increase in cAMP
concentration as the intracellular event leading VSMCs to adopt a stel-
late phenotype [17–20]. We therefore investigated the possible associ-
ation of the IL-1β-dependent transdifferentiation of VSMCs with the
increase in intracellular [cAMP], using a FRET-based biosensor for
cAMP (TEpacVV, [21]). This technique can be used to monitor real-
time changes in intracellular [cAMP] in living cells. These experiments
showed that the increase in intracellular [cAMP] in response to IL-1β
stimulation was due to the secretion of a unique autocrine/paracine
mediator, PGE2. By interacting with the EP4 receptor, PGE2 stimulates
cAMP production, in turn activating PKA and destabilizing the actin
cytoskeleton and focal adhesions.Table 1
Summary of qPCR primer sequences.
Gene family Target genes Forward primers (5′-3
Eicosanoids COX-2 ggaagtctttggtctggtg
sPLA2 IIA atggcctttggctcaat
PTGES agctaggtgtgtggatctc
Chemokines CXCL1 gactccagccacactccaac
CXCL2 ggatcgtccaaaagatactga
CXCL3 ggctcctcaatgctgcac
CXCL5 cactgccacagcatcgag
CXCL10 atgaacccaagtgctgctgt
CX3CL1 cgtgccacaagatgacctc
CCL2 agcatccacgtgctgtctc
CCL3 gcgctctggaacgaagtct
CCL20 ggggtactgctggcttacct
GM-CSF catctctaatgagttctccatcc
VEGF-A ctatgtgctggctttggt
Interleukins IL6 tggtcttctggagttccg
Contractile markers Calponin cagccaggctggcatga
SM22-α tatggcagcagtgcagag
Smoothelin gcagtatgaagactacatttac
SM-MHC tgagaggaagaagatggctca
PKA subunits PRKACA cggggtcctcatctacga
PRKACB gagtacctggccccagagat
PRKAR1A caataatgaatgggcaacca
PRKAR1B gatcccccaacgaggagtat
PRKAR2A tggatgtgatcggggaaa
PRKAR2B gtgctctgtggggtttgg
Housekeeping gene Cyclophilin A tgctggaccaaacacaaatg2. Materials and methods
2.1. Reagents
DMEM, type I collagen from calf skin, L-glutamine, penicillin,
streptomycin, fatty acid-free bovine serum albumin, isobutyl-L-methyl-
xanthine (IBMX), FITC-conjugated monoclonal anti-vinculin clone
hVIN-1, and monoclonal mouse anti-β-actin clone AC-15, were
obtained from Sigma Aldrich, Saint Quentin Fallavier, France.
Rabbit anti-hospho PKA substrate antibody (100G7E) was obtained
from Cell Signaling, Leiden, The Netherlands. We purchased 8-(4-
chlorophenylthio)-2′-o-methyladenosine-3′, 5′-cyclic monophosphate
sodium salt (8-pCPT-O-Me-cAMP), N6-benzoyladenosine-3′, 5′-cyclic
monophosphates (6BNZ-cAMP) and 8-bromoadenosine-3′, 5′-cyclic
monophosphorothioate, and Rp- isomer (Rp-8-Br-cAMPS) from BioLog,
Bremen, Germany. Forskolin (FSK)was obtained fromTocris Bioscience,
Bristol, UK. Fetal calf serum (FCS), FluoroBrite™DMEM and collagenase
were purchased from Gibco BRL, Cergy Pontoise, France. Elastase, and
LightCycler-DNA Master Plus SYBR Green were obtained from Roche
Diagnostics, Meylan, France. Alexa Fluor® 594-conjugated phalloidin,
OPTI–MEM, Fluorobrite DMEM and Lipofectamine® RNAiMAX Reagent
were obtained from Invitrogen, Saint Aubin, France. Oligonucleotides
were obtained from Euroﬁns Genomics, Ebersberg, Germany. Recombi-
nant human IL-1β, rat TNFα and IFNγ were obtained from Peprotech,
Neuilly-sur-Seine, France. The PGE2 receptor antagonists, L-798 106
(EP3R), SC51322 (EP1R) and ONO AE3208 (EP4R) were obtained from
Tocris Bioscience, Bristol, United Kingdom.
2.2. Cell culture
Rats were euthanized by the i.p. injection of pentobarbital
(300 mg/kg) and VSMCs were isolated as previously described [22].
The university ethics committee approved the experiments on rats and
all animal procedures conformed to European Directive 2010/63/EU.
The VSMC response to IL-1β decreased rapidly with successive cell
passages. We therefore performed all experiments on cells that had
been subcultured only one to three times. We coated the wells of′) Reverse primers (5′-3′) Accession numbers
tcttgatcgtctctcctatcagta NM_017232.3
gcaaccgtagaagccata NM_031598.3
acaatcttctgtcctttgctttat NM_021583.3
cagcgctgcacagagaag NM_030845.1
ac ggtacaggagcccatgttctt NM_053647.1
ggccacaacagtccctga NM_138522.1
ttaagcaaacacagcgtagctc NM_022214.1
gtctcagcgtctgttcatgg NM_139089.1
ctgtgctgtctcgtctccag NM_134455.1
gatcatcttgccagtgaatgag NM_031530.1
gaatttgccgtccataggag NM_013025.2
ggcagcagtcaaagttgctt NM_019233.1
ag cccgtagaccctgcttgtat NM_053852.1
gagatagagtatatcttcaagccg NM_001287108.1
agatatgaactagggtttcagtattg NM_012589.2
ccatctgcaagctgacg NM_031747.1
ctttcttcataaaccagttggga NM_031549.2
cattg tcagttctgctctctgttg NM_001013049.2
tgtagtttctgtctggcagctt NM_001170600.1
tgaagtgggatgggaacc NM_001100922.1
ccaccagtccactgccttat NM_001077645.1
atcaaagccagctctccaaa NM_013181.1
gcagggcaatctctccaa NM_001033679.1
aagctgtcggccttttca NM_019264.2
ttcctctttttggcattgtttt NM_001030020.1
cttcccaaagaccacatgct NM_017101.1
3237K. Blirando et al. / Biochimica et Biophysica Acta 1853 (2015) 3235–3247culture slides with collagen by incubation overnight. The wells were
then seeded with cells at a density of 5000 cells/cm2, in DMEM con-
taining 1 g/l glucose, 4 mM L-glutamine, 10% fetal calf serum, 100 U/ml
penicillin, 100 μg/ml streptomycin, and the plates were incubated for
96 h, at 37 °C, under an atmosphere containing 5% CO2. The cells were
starved by incubation in serum-free DMEM for 7 to 16 h before treat-
ment. We prepared conditioned medium for FRET experiments, by
starving the cells in serum-free Fluorobrite DMEM, to minimize back-
ground ﬂuorescence.Fig. 1. Effect of pro-atherogenic cytokines on VSMCmorphology as a function of cytoskeletal or
with 5 ng/ml IL-1β, 10 ng/ml TNFα or 10 ng/ml IFNγ. B. Immunostaining for ﬁlamentous act
594-conjugated phalloidin (red) and FITC-coupled monoclonal anti-vinculin antibody (green)
independent experiments.2.3. Transfection with a small interfering RNA (siRNA)
VSMCs were grown to about 80% conﬂuence, and were maintained
for 2 h in antibiotic-free DMEM containing 1 g/l glucose, 4 mM L-gluta-
mine, 10% FCS. Transfection was then performed by adding 0.25% Lipo-
fectamine and 1 nM siRNA in 12.5% Opti-MEM and incubating the cells
for 24 h. The cells were then starved of serum and treated for 48 h.
The siRNAs used were a mixture of 30 different sequences called
siPools purchased from Sitools Biotech GmbH (Planegg, Germany) andganization. A. Phase-contrast microscopy of cell morphology 12, and 72 h after stimulation
in (F-actin) and vinculin 72 h after the treatment of PFA-ﬁxed VSMCs, with Alexa Fluor
visualized by ﬂuorescence microscopy. The images shown are representative of at least 3
Fig. 2. Effect of pro-atherogenic cytokines on the phosphorylation level of PKA substrates. A. Western-blot analysis of PKA substrate phosphorylation with β-actin as a loading control
(left panel). Western-blot quantiﬁcation for phosphorylated PKA substrates (right panel). The data shown are the means ± SEM of 5 independent experiments. *, P b 0.05, versus
vehicle-treated cells in a Kruskal-Wallis test followed by Dunn's multiple comparison test.
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(NM_001033679.1).
2.4. Protein extraction and Western blot analysis
Cells were washed with ice-cold phosphate-buffered saline (PBS)
and scraped into lysis buffer (25 mM Tris–HCl, pH 7.5, 150 mM NaCl,
1% NP40, 1% sodium deoxycholate, 0.1% SDS) supplemented with Halt
phosphatase and protease inhibitor cocktail (Pierce, Thermo-Scientiﬁc,
Villebon sur Yvette, France). Cell lysates were incubated on a rotating
wheel for 15min at 4 °C. The lysateswere then cleared by centrifugation
(13,000 ×g for 15 min at 4 °C), and the supernatant was collected. Cell
extracts (30 μg of protein) were analyzed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis on 4–12% gradient gels (Invitrogen
NuPAGE system) and the resulting bands were transferred onto nitro-
cellulosemembranes (0.45 μM). Themembraneswere blocked by incu-
bation for 1 h at room temperature with Tris-buffered saline
supplemented with 0.1% Tween 20 (TBS-T: 20 mM Tris–HCl, pH 7.5,
100 mM NaCl, 0.1% Tween 20) and 5% bovine serum albumin, and
then incubated overnight with primary antibodies (1/1000) in TBS-T
supplemented with 5% bovine serum albumin, at 4 °C. The membranes
were then washed in TBS-T and incubated with horseradish peroxidase
(HRP)-conjugated secondary antibodies for 1 h at room temperature.
Signals were detected with the ECL detection system, following the ex-
posure of Fujiﬁlm LAS-300, FujiﬁlmMedical Systems, Stamford, CT, USA.
We used β-actin detection to check for equal protein loading and trans-
fer efﬁciency. The densitometry data obtained were analyzed with
ImageJ software and normalized relative to the density of β-actin.
2.5. Absolute quantiﬁcation of mRNA copy number
Speciﬁc 250 to 1000 bp amplicons were generated from the RNA by
RT-PCR and puriﬁed. Each amplicon was assayed and the number of
copy was calculated according to its size in bp. Serial dilutions of
known concentration were used in qPCR, to determine the ﬁt coefﬁ-
cients of the relative standard curve. Absolute quantiﬁcation was per-
formed by interpolation of the PCR signal (Cq) into this standard
curve with the Livak–Schmittgen equation [23]. The forward and re-
verse primers used were as follows: PKACα, cccgttcctggtcaaacttg,ggggtgtggagtggatgtta; PKACβ cgaagtggagagcgtgaaag, gtcttgatgtcact
cacgcc; PKAR1α, gcgctgaggtttacactgag, tctcagacggacagtgacac; PKAR1β,
cacactgaggaaacgcaaga, catagggaatgggtcacagg; PKAR2α, caataccccga
gagctgcta, gaagcaaagtggaaggtggg; PRKAR2β, ggtcaaagaaggggaacacg,
taactgcttcactaacgcgc.
2.6. Quantitative PCR assay
Total RNAwas extractedwith the Reliaprep™ RNA isolation kit from
Promega, Charbonnieres, France. Total RNA (0.5–1 μg) was reverse-
transcribed with the M-MLV reverse transcriptase system and 1 μM
Oligo-dT (Invitrogen, Saint Aubin, France). We carried out qPCR with
primers designed with the Roche Universal Probe Library Assay Design
Center, with a LightCycler® 480SYBR Green I Master system (Roche Di-
agnostics, Meylan, France). Cyclophilin A (CycloA) was used as the
housekeeping gene. PCRwas performedwith the following thermal set-
tings: denaturation and enzyme activation at 95 °C for 5 min, followed
by variable numbers of cycles of 95 °C for 10 s, 60 °C for 15 s, and 72
°C for 10 s. Ampliﬁcation was monitored online and the reaction
was stopped at the end of the logarithmic phase. Melting curve anal-
ysis was carried out to check the speciﬁcity of PCR. Controls and
water blanks were included in each run, and all gave negative results.
The qPCR analysis of serial dilutions of a mixture of cDNAs indicated
that ampliﬁcation efﬁciency was close to 100% for all the genes stud-
ied. The primer sequences used to amplify the cDNAs are shown in
Table 1.
2.7. Cytokine array
Conditioned medium from cultures of VSMCs treated with vehicle,
IL-1β (5 ng/ml), TNFα (10 ng/ml) or IFNγ (10 ng/ml) for 72 hwas incu-
bated with Proteome Proﬁler Rat Cytokine Array Panel A membranes
(R&D Systems, Minneapolis, Minnesota, USA). These concentrations of
cytokines were used throughout the study.
2.8. Immunocytochemistry
Collagen-coated coverslips were seeded with 5000 cells/cm2. The
cells were grown to conﬂuence and starved of serum, and they were
Fig. 3. IL-1β, TNFα and IFNγ do not increase intracellular cAMP concentration in an acute manner. Changes in intracellular [cAMP] were measured with the TEpacVV biosensor, by wide-
ﬁeld ﬂuorescence imaging on untreatedVSMCs. Drugswere added to the bath for the period indicated by the bar on the graph: 10 μM isoproterenol (positive control, A), 5 ng/ml IL-1β (B),
10 ng/ml TNFα (C) or 10 ng/ml IFNγ (D). Left panels. Microscopy ﬁelds shown in black and white (upper left) are representative of ﬂuorescence emission at 535 nm. The ratio was de-
termined over individual cells within regions of interest (ROI) delimited with colored contours. The F480/F535 ratio, indicative of biosensor activation, was calculated for each pixel in
the whole image. Pseudocolored images representing the F480/F535 emission ratio provide an indication of intracellular [cAMP] (a) before treatment, (b) during cytokines treatments
and (c), with 10 μM forskolin +200 μM IBMX, to maximize biosensor ratio levels. The calibration square (top right) indicates ﬂuorescence intensity (in counts/pixel/s) horizontally
and F480/F535 ratio vertically. Right panels. Time course of F480/F535 ratio measurements averaged over individual ROIs. Each trace indicates F480/F535 emission ratio measurements
for individual cells over time, corresponding to the ROI delimiting each cell. Gray traces correspond to the F480/F535 emission ratio of cells outside the displayed region. The average of all
traces is plotted as a thick black line. The data and images shown are representative of 4 independent experiments.
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ﬁxed by incubation in 2% sucrose and 3% paraformaldehyde in PBS for
15 min at room temperature, and permeabilized by incubation with
0.2% Triton X-100 in PBS for 5 min. Non-speciﬁc sites were blocked by
incubation with 5% FCS in PBS. The cells were stained for actin and vin-
culin, by incubation for 2 h at 21 °C with Alexa Fluor® 594-conjugated
phalloidin and an FITC-conjugated monoclonal anti-vinculin antibody,
in PBS containing 5% FCS. The cell nuclei were stained with 4′,6′-
diamidino-2-phenylindole (DAPI). The coverslips were mounted in
Dako ﬂuorescence mounting medium (Dako, Carpinteria, California,
USA) and examined with a Nikon Diaphot 300 microscope (Nikon,
Tokyo, Japan).
2.9. PGE2assay
PGE2 secretion was evaluated with an enzyme immunoassay kit
from Cayman Chemical SPI-BIO, Massy, France.
2.10. Generation of TEpacVV cAMP biosensor-encoding adenovirus
TEpacVV, a FRET-based sensor for cAMP, consists of a cAMP-binding
domain from the exchange protein directly activated by cAMP 1
(Epac1) sandwiched between the ﬂuorescent donor mTurquoise and
acceptor cpVenus-Venus proteins [24]. The cDNA encoding the
TEpacVV biosensor was inserted between the BglII and XhoI restriction
sites of the pShuttle plasmid (Agilent Biotechnology, Santa Clara, Cali-
fornia, USA). The pShuttle- TEpacVV was linearized by digestion with
PmeI and inserted into the pAdEasy-1 vector by homologous recombi-
nation. Recombinant viral vectors carrying the TEpacVV biosensor were
produced in the HEK-293 T cell line at UMR1089, Nantes, France.
2.11. Dynamics of cAMP production
VSMCs on collagen-coated glass coverslips were incubated with the
TEpacVV-encoding adenoviral vector (~100 particles per cell) for 24 h at
37 °C, under an atmosphere containing 5% CO2. Coverslips were placed
in a microscope chamber, continuously perfused (2 ml/min) with a
buffer containing 125 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 1.25 mM
NaH2PO4, 26 mM NaHCO3, 25 mM glucose and maintained at 32 °C,
saturated with 5% CO2–95% O2. TNFα, IFNγ or IL-1β was added during
the perfusion.
Conditioned medium for the FRET experiments was obtained by
treating VSMCs with IL-1β, TNFα or IFNγ for 72 h in FluoroBrite™
DMEM, a medium specially developed for the ﬂuorescence imaging of
live cells. We measured cAMP production in response to the addition
of conditioned medium, in cells that had previously undergone
transdifferentiation in response to exposure to IL-1β, TNFα or IFNγ for
48 h and had then been starved overnight. Ratiometric analyses were
performed as follows: ﬂuorescence was induced at an excitation wave-
length of 435 nm, and the ﬂuorescence emitted by the donor and accep-
tor was monitored with a dichroic mirror (455 DCLP) and alternating
emission ﬁlters for donor (470 ± 20 nm) and acceptor (530 ± 25
nm). Pairs of images were recorded with a CCD camera (Orca-ER,
Hammamatus), at 20-s intervals. Changes in intracellular [cAMP] are
expressed as the ratio of donor ﬂuorescence (F480nm) to acceptor
ﬂuorescence (F535nm). The ratios were multiplied by a constant such
that the baseline ratio was 1 in basal conditions. The maximum ratio
change (Rmax) was obtained by stimulating cells with 10 μM FSK and
200 μM IBMX. The data shown are representative of three independent
experiments, with the acquisition of 10–15 cells per experiment.
2.12. Time-lapse video microscopy
Sixteen hours before any treatment, cells were starved in serum-free
DMEM. Changes in their morphology were then monitored by time-
lapse video microscopy. Phase-contrast images (3 ﬁelds/well) werecaptured with a 20× objective, at 2.5-minute intervals, for 18 h. Images
were captured with an inverted microscope (DMI 6000B from Leica)
equipped with a cell incubation chamber, a motorized stage, and a
coolSNAP HQ2 CCD camera. All operations were controlled with
Metamorph software (version 7.1).
2.13. Statistics
All data are presented asmeans± SEMof at least three independent
experiments. Graphical representationswere generated and the statisti-
cal signiﬁcance of differences between groups were assessed with
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). Pairwise
comparisons of groups were carried out with two-tailed Mann–
Whitney tests. For comparisons of multiple groups, we used Kruskal–
Wallis tests followed by Dunn's multiple comparison tests. Differences
were considered signiﬁcant if P b 0.05.
3. Results
3.1. IL-1β increases intracellular [cAMP] via one or several
autocrine/paracrine factors
Light microscopy (Fig. 1A and Supplementary Videos 1–4) showed
that IL-1β was the only cytokine of those tested capable of inducing
the transition to a stellate form in VSMCs. In vitro, this phenomenon
peaks about 12 h after stimulation, tending to decrease thereafter, as
shown by time-lapse imaging. It is followed by a secondwave of transi-
tion to a stellate morphology beginning 48 h after the addition of IL-1β
and intensifying until 72 h after the addition of this cytokine. The cAMP-
dependent stellate morphology of VSMCs (induced by the β-adrenergic
receptor agonist isoproterenol) is characterized by a loss of focal adhe-
sions and the disassembly of actin stress ﬁbers [20]. We therefore also
stained cells for actin and the focal adhesion marker vinculin. IL-1β dis-
rupts focal adhesions and actin stress ﬁbers, whereas neither TNFα nor
IFNγ modiﬁes the cytoskeleton (Fig. 1B). However, the treatment of
VSMCs with IL-1β, TNFα or IFNγ for 48 h, followed by an analysis of
mRNA levels for four major contractile markers showed that all these
cytokines inhibited the expression of at least some of these markers,
attesting to their efﬁcacy. All three compounds decreased the levels of
SM-MHC and calponin (Supplementary Fig. S2), but only IL-β and
TNFα decreased SM22 (by ~90 and 50%, respectively) and smoothelin
(by ~75 and 50%, respectively)mRNA levels to any great extent. Consis-
tent with a cAMP-dependent phenomenon, stellate cells were also ob-
tained following an increase in intracellular [cAMP] induced by
forskolin (FSK), a speciﬁc activator of adenylyl cyclases (ACs). This effect
was observed within a few minutes of FSK application and was main-
tained for up to 4 h (Supplementary Fig. 1B and Supplementary Video
5). Together with the demonstration that IL-1β was the only cytokine
of those tested to increase PKA activity signiﬁcantly (as shown by mea-
suring the phosphorylation of PKA substrates, Fig. 2), these data demon-
strate that IL-1β-inducedVSMC transdifferentiation is different from that
induced by the other cytokines tested. These data also suggest that this
effect is at least partly dependent on the cAMP signaling pathway.
We investigated whether the IL-1β-dependent transdifferentiation
of VSMCswas associatedwith an increase in intracellular cAMP concen-
tration, using the FRET biosensor TEpacVV [21]. We monitored changes
in intracellular cAMP concentration by calculating the ratio of donor
ﬂuorescence (F480nm) to acceptor (F535nm) ﬂuorescence. The
baseline ratio at the start of the experiment was set to 1 and the
maximum ratio change (Rmax) was systematically determined at the
end of the experiment, by adding 10 μM forskolin, an activator od
adenylyl cyclases, and 200 μM isobutyl-L-methylxanthine (IBMX), a
broad-spectrum phosphodiesterase inhibitor. Incubation with isopro-
terenol (used as a positive control) greatly increased the ratio to
90.0 ± 1.1% of the maximal ratio change (n = 4, P b 0.001), but none
of the cytokines tested induced a detectable increase in intracellular
Fig. 4.Conditionedmedium(CM) from IL-1β-treated cells increases cAMPconcentration and induces a change inVSMCmorphology. CMwas collected after the treatment ofVSMCswith vehicle,
IL-1β (5 ng/ml), TNFα (10 ng/ml) or IFNγ (10 ng/ml) for 72 h. Recipient cellswere allowed to undergo transdifferentiation under the same treatment conditions for 48 h andwere then starved
overnight. The data and images shown are representative of at least 3 independent experiments. Left and middle panels. Vehicle- (A), IL-1β- (B), TNFα- (C) or IFNγ-treated VSMCs (D) were
perfusedwith the corresponding conditionedmedium for the time indicated by the horizontal bar on the graphs. Left panels. See Fig. 3, legend for the left panel. Middle panels. See Fig. 3, legend
for the right panel. Right panels. Phase-contrast microscopy of the morphological phenotype of VSMCs induced by 1 h of treatment with vehicle-CM, IL-1β-CM, TNFα-CM and IFNγ-CM.
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to induce the transition to a stellate cell morphology, we hypothesized
that any increase in cAMP concentration might be dependent on the
production of autocrine/paracrine factors.
Weused conditionedmediumobtained fromVSMCs treatedwith ve-
hicle, IL-1β, TNFα or IFNγ for 72 h (referred to as vehicle-CM, IL-1β-CM,
TNFα-CM and IFNγ-CM, respectively) to test this hypothesis. IL-1β-CM
immediately triggered a large increase in intracellular cAMP concentra-
tion (up to 34.5 ± 3.8% of the maximum ratio, n=4, P b 0.01), whereas
the other conditionedmedia hadno effect on cAMP (Fig. 4 (left andmid-
dle panels) and Table 2). Consistent with this ﬁnding, the addition of IL-
1β-CMadded to naive/contractile cells also rapidly (within less than 2h)
triggered the transition to a stellate cell morphology (Fig. 4B, right
panels), whereas treatment with IL-1β took at least 12 h to achieve the
same effect (Fig. 1A). The other two conditioned media (TNFα-CM and
IFNγ-CM) were inefﬁcient regardless of the mode of monitoring used
(dynamics of cAMP production or change in cell shape). Thus, stimula-
tionwith IL-1β leads to the release of one or several autocrine/paracrine
factors, triggering an increase in the intracellular concentration of cAMP.
These ﬁndings also demonstrate that cAMP production is a hallmark of
IL-1β-dependent VSMC transdifferentiation.
3.2. The IL-1β-dependent increase in intracellular [cAMP] involves PGE2
secretion and PGE2 receptor isoform 4 (EP4)
As a ﬁrst step towards identifying the factors involved,we compared
the secretion proﬁles of IL-1β, TNFα and IFNγ, in terms of their induc-
tion of the inﬂammatory cytokines/chemokines and enzymes involved
in eicosanoid/PGE2 synthesis at the mRNA and/or protein level. For
most of the mRNAs studied, signiﬁcant induction was observed with
at least two of the cytokines tested, IL-1β and TNFα, or IFNγ and
TNFα, indicating a very low likelihood of a role in stellate cell morphol-
ogy for these mRNAs (Table 3 and Fig. 5 left panels A and B). However,
the mRNAs encoding COX-2, CCL3, and VEGF-A were speciﬁcally and
signiﬁcantly induced by IL-1β. It was also clear from our results that
i) TNFα was the most potent cytokine for CCL5 mRNA synthesis;
ii) IFNγ, which had no effect on the CCL5, CCL3, COX-2 and VEGF-A
mRNAs, strongly induced synthesis of the CXCL10 mRNA encoding the
chemo-attractant of T lymphocytes and monocytes. Using a cytokine
array allowing the detection of 29 different inﬂammatory mediators
and a PGE2 assay, we were able to expand our results further, to show
that, in addition to triggering the expression of CCL3 and VEGF, IL-1β
also induced high levels of CXCL2, GM-CSF and IL6 expression, and
PGE2 secretion. It is also clear that i) IFNγ induces the production of
small amounts of CXCL1, CX3CL1 and CCL5; ii) contractile vehicle-
treated VSMCs have very low levels of secretory activity, because only
CXCL1 and the tissue inhibitor matrix metalloproteinase-1 are detected
in their culture medium.
Our data and those obtained for human VSMCs [25] suggested that
PGE2 was a potentially good candidate for relaying the increase in cAMP
concentration in response to IL-1β, particularly as PGE2 triggered the tran-
sition to a stellate VSMC morphology within an hour, or even faster in
some cases, depending on the number of cell subcultures (SupplementaryTable 2
Amplitude of the dynamic cAMP response triggered by cytokine-treated VSMC condi-
tioned medium. The amplitude of the response is indicated by the mean for the % of the
maximum response (Rmax) obtained adding 10 μM forskolin +200 μM IBMX. The data
presented are the means ± SEM of 4 independent experiments on 10–30 individual cells
per condition. Signiﬁcance was evaluated in Kruskal–Wallis tests followed by Dunn's
multiple comparison tests. **, P b 0.01 versus vehicle-treated cells.
Conditioned medium (CM) Mean (% of Rmax) ± SEM
Vehicle-CM 1.39 ± 0.76
IL-1β-CM 34.5 ± 3.8**
TNFα-CM 3.80 ± 2.4 n.s
IFNγ-CM 2.37 ± 1.27 n.sVideo 6). We therefore repeated the experiments carried out with IL-1β-
CM, successively blocking each of the three PGE2 receptors expressed by
VSMCs.1 Each dose of antagonist was selected on the basis of published
data, to yield maximal inhibition corresponding to 20 times the Ki value
[26–28]. Neither the EP1 antagonist nor the EP3 antagonist (SC51322,
L798,106, respectively) affected the increase in intracellular [cAMP] in-
duced by IL-1β-CM (Fig. 6A and C). Conversely, when the EP4 antagonist
ONO AE3208 was applied, intracellular [cAMP] rapidly (within 2 min)
returned to baseline levels. Consistently with the observation that the
transition to a stellate shapewas associatedwith an increase in intracellu-
lar [cAMP], ONO AE3 was the only compound capable of blocking this
process efﬁciently in IL-1β-CM- or PGE2-treated cells. In light of these
ﬁndings and the observation that very similar results were obtained
when IL-1β-CM was replaced with PGE2 (Fig. 6B and D), we conclude
that the autocrine/paracrine factor secreted upon IL-1β stimulation in
VSMCs is unique and can be identiﬁed as PGE2.
3.3. The transition to a stellate morphology in VSMCs involves PKA
The regulation of cellular properties by cAMP ismediated principally
by cyclic nucleotide-gated ion channels, the exchange proteins directly
activated by cAMP (Epac-1 and −2)2 and/or protein kinase A (PKA).
The treatment of naïve/contractile VSMCs with increasing doses of
6BNZ (a speciﬁc activator of PKA) led to a dose-dependent increase in
the number of stellate cells (Fig. 7A); 8-pCPT-O-Me-cAMP, an activator
of Epac, was ineffective up to a dose of 500 μM. The speciﬁcity of 6BNZ
was conﬁrmed by the prevention of its effects on cell morphology at a
concentration of 250 μM by the prior treatment of cells with various
doses (100–500 μM) of Rp-8-Br-cAMP (Supplementary Fig. S3) or
RP-8-CPT-cAMP (data not shown), both of which inhibit PKA. The
treatment of VSMCs allowed to transdifferentiate in the presence of
IL-1β (5 ng/ml for 48 h) with 100 μM 6BNZ for 3 h greatly increased
the number of stellate cells (Fig. 7B). By contrast, the same concentra-
tion of 6BNZ had almost no effect on contractile/naive cells (Fig. 7A).
Epac stimulation of VSMCs transdifferentiating in response to IL-1β had
no effect, regardless of the batch of 8-pCPT-O-Me-cAMP used (Fig. 7B).
These results suggest that the IL-1β-induced/cAMP-dependent change
in shape of VSMCs is mediated by PKA activation.
PKA is a holoenzyme with four subunits, two of which are catalytic,
the other two being regulatory. The association of regulatory subunits
R1α/R1β with any of the catalytic subunits (Cα, Cβ or Cγ) deﬁnes
PKA1, whereas an association of the regulatory subunits R2α/R2β
with any of the catalytic subunits results in PKA2 and an inhibition of
catalytic activity [29]. These two enzymes also differ in terms of their lo-
cation and afﬁnity for cAMP. Rodents lack the catalytic subunit Cγ. A
comparison of mRNA levels for each of the subunits between naive/
contractile and IL-1β-treated VSMCs showed that the contractile/naïve
VSMCs produced all four regulatory (R) subunits, the most abundant
being R1α (~65%), followed by R2α (~22%), R2β (~10%) and R1β
(~3%); Cα and Cβ accounted for ~70% and 30% of catalytic subunits,
respectively (Fig. 7C, left panel). IL-1β treatment induces a signiﬁcant
40-fold increase in R1β gene expression 48 h after stimulation
(Fig. 7C, left panel), but R1α expression nevertheless predominated.
The levels of R2α and R2β mRNA were affected much less, if at all, by
IL-1β. An analysis of catalytic subunit expression during the process of1 Type E2 prostaglandinmay activate neighboring cells through four differentGprotein-
coupled receptor subtypes, EP1-4. Each of these receptor subtypes is encoded by a differ-
ent gene and has unique pharmacological features. Contractile and fully secretory rat
VSMCs (obtained by incubation with 10 ng/ml IL-1β, 72 h) express the same pattern of
PGE2 receptor subtype transcript production: 1, 3, 4, but not 2 (Purdy and Arendshorst,
2000; Clément et al., 2006).
2 Epacs are GDP/GTP exchange factors for small G proteins of the Ras family, including
Rap1A andB, Rap2A and B, andHras (Schmidt,M., F.J. Dekker, andH.Maarsingh, Exchange
protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regula-
tion of diverse biological functions. Pharmacol Rev., 2013. 65(2): p. 670–709).
Table 3
Levels of mRNAs encoding inﬂammatory markers in transdifferentiated VSMCs. Conﬂuent rat VSMCs were serum-starved and treated with vehicle, IL-1β (5 ng/ml), TNFα (10 ng/ml) or
IFNγ (10 ng/ml). Relative levels of mRNAs encoding inﬂammatory markers, 48 h after stimulation, expressed as a fold-change with respect to vehicle. The results were ﬁrst normalized
with respect to cyclophilin A (PPIA) and the data shown are the mean value ± SEM of 7 or 8 independent experiments. Differences between groups were evaluated in Kruskal–Wallis
tests followed by Dunn's multiple comparison tests. *, P b 0.05, **, P b 0.01 and ***, P b 0.001 versus vehicle-treated cells.
Fold-change with respect to vehicle
Gene family Genes Vehicle IL-1β TNFα IFNγ
Eicosanoid metabolism COX-2 1.32 ± 0.38 175 ± 77 *** 1.4 ± 0.3 n.s 1.5 ± 0.3 n.s
sPLA2 IIA 1.30 ± 0.36 33,579 ± 6858 *** 4197 ± 1445 ** 405 ± 271 n.s
PTGES1 1.09 ± 0.18 1399 ± 359 *** 15.18 ± 3.95 * 3.96 ± 1.57 n.s
Cytokines/Chemokines CXCL1 1.63 ± 0.6 859 ± 210 *** 63.4 ± 9.4 * 25.5 ± 12.4 n.s
CXCL2 1.95 ± 0.89 17,862 ± 8768 *** 326.2 ± 130 *** 9.18 ± 2.88 n.s
CXCL3 1.08 ± 0.15 20,027 ± 7272 *** 546 ± 98 * 36.5 ± 23.2 n.s
CXCL5 2.18 ± 1.11 18,572 ± 3777 *** 1162 ± 204 * 30.24 ± 9.06 n.s
CXCL10 1.19 ± 0.27 9.34 ± 2.62 n.s 30.48 ± 3.49 * 5007 ± 974 ***
CX3CL1 1.19 ± 0.22 70.98 ± 14.72 *** 42.1 ± 3.45 ** 22.24 ± 6.25 n.s
CCL2 1.07 ± 0.17 289 ± 38 *** 131 ± 7 ** 32.2 ± 9.8 n.s
CCL3 1.01 ± 0.09 1744.36 ± 632.6 *** 1.30 ± 0.17 n.s 2.12 ± 0.75 n.s
CCL5 1.19 ± 0.28 3498 ± 1577 ** 21,337 ± 5183 *** 606 ± 191 n.s
CCL20 1.33 ± 0.53 5915 ± 1123 *** 569 ± 105 ** 62.44 ± 38.5 n.s
GM-CSF 1.02 ± 0.08 11,029 ± 2598 *** 67.00 ± 7.7 * 2.61 ± 0.81 n.s
IL6 1.14 ± 0.18 1043 ± 143 *** 19.26 ± 3.16 * 7.32 ± 2.92 n.s
VEGF-A 1.10 ± 0.18 4.02 ± 0.96 ** 1.44 ± 0.16 n.s 1.53 ± 0.19 n.s
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gardless of the cytokine used (Fig. 7C left panel and data not shown).
Based on these data, we decided to silence R1α to conﬁrm theFig. 5. Inﬂammatory secretome induced by IL-1β, TNFα and IFNγ. VSMCs were treated with ve
mRNA after 48 h of stimulation, expressed as fold-changeswith respect to vehicle. The diagram
panels A and B. Analysis of the cell medium 72 h after stimulation, in amembrane-based antibo
are presented as themean±SEMof 6 and 8 independent experiments respectively. **, P b 0.01 v
tests. The results of the cytokine array analysis are representative of 2 independent experimeninvolvement of PKA in this process. In many cell types and in vivo, the
disruption of PKAR1α is associated with an increase in the catalytic ac-
tivity of PKA [30–32]. Consistent with a role for PKA in stellate cellhicle, IL-1β (5 ng/ml), TNFα (10 ng/ml) or IFNγ (10 ng/ml). Left panels A and B. Levels of
is based on the data shown in Table 3 (mean± SEM of 8 independent experiments). Right
dy array (A) and by ELISA (B). Data for the PGE2 assay and inﬂammatory genemRNA levels
ersus vehicle-treated cells in Kruskal-Wallis tests followed byDunn'smultiple comparison
ts.
Fig. 6. Blocking EP4 receptors suppresses the response to conditionedmedium from IL-1β-treated VSMCs (IL-1β-CM, A) and PGE2 (B). Panels A and B. Intracellular [cAMP] in naive VSMCs
treated with (A) IL-1β-CM or (B) 50 nM PGE2. The various EP antagonists were added successively, as indicated in the ﬁgure. The antagonist concentrations were as follows, 280 nM for
SC51322 (EP1), 6 nM for L798,106 (EP3) and 26 nM for ONOAE3208 (EP4). The black line indicates the duration of treatment. See the legend to the right panel in Fig. 3 for details. Panels C
andD. Quantiﬁcation of the changes in cAMP concentration induced by (C) IL-1β-CM or (D) 50 nMPGE2 in the presence or absence of the EP antagonists. n.s., non-signiﬁcant, ***, P b 0.001
versus vehicle-treated cells in Kruskal–Wallis tests followed by Dunn'smultiple comparison tests. Panels E and F. Phase-contrastmicroscopy of the changes in VSMCmorphology induced
by (E) IL-1β-CM or (F) 50 nM PGE2 in the presence or absence of the EP antagonists. The data and images shown are representative of 3 independent experiments.
3244 K. Blirando et al. / Biochimica et Biophysica Acta 1853 (2015) 3235–3247morphology, knocking down R1α expression mimicked the effect of IL-
1β/PGE2 on cell morphology, resulting in destabilization of the actin cy-
toskeleton and focal adhesions (as shown by immunostaining for F-actin and vinculin, respectively). Conversely, knocking down R1β ex-
pression had no impact (Fig. 7D and Supplementary Fig. S4B). Despite
the increase in R1β mRNA levels observed on IL-1β treatment, the
3245K. Blirando et al. / Biochimica et Biophysica Acta 1853 (2015) 3235–3247silencing of R1β in PGE2-treated cells did not prevent these cells from
developing a stellate phenotype. The efﬁcacy and speciﬁcity of R1α
and β siRNAs were demonstrated by the determination of R1α and β
mRNA levels after transfection (Supplementary Fig. S4A).
4. Discussion
The transdifferentiation of VSMCs in the inﬂammatory context of ath-
erogenesis plays a key role in atherosclerosis, as highlighted by the re-
cent study by Shankman et al. [15]. Indeed, these authors showed that
the contribution of VSMCs to atherosclerotic lesions had been greatly
underestimated, due to their ability to develop the expression of macro-
phage, mesenchymal stem cell and/or myoﬁbroblast markers in lesions.
Given the known role of pancreatic stellate cells in acute episode of pan-
creatic injury [33], it is possible that the stellate cells of the artery wall
serve as extracellular matrix-producing cells or myoﬁbroblasts, increas-
ing plaque stability. However, chronic IL-1β-treatment reduces the ex-
pression by VSMCs of proﬁbrotic and/or proproliferative compounds,
such as connective tissue growth factor and insulin growth factor-1
(Blirando et al. unpublished data). It therefore appears more likely that
the aortic stellate cells ﬁrst produce large amounts of ECM proteins and
then undergo a switch towards a phenotypewith high levels ofMMP ac-
tivity. This remains to be demonstrated, but is consistent with the two
waves of stellate cell development observed in vitro in response to
short- and long-term stimulation with IL-1β.
We show that, of the three key pro-atherogenic cytokines tested
(IL-1β, TNFα and IFNγ), IL-1β was the most potent inducer (in terms
of the numbers and amounts of secreted molecules) of the VSMC in-
ﬂammatory response, triggering the release of substantial amounts of
CCL3, GM-CSF, IL-6, VEGF-α, CX3CL1, CXCL1, CXCL5 and PGE2. Consis-
tent with published ﬁndings, IFNγ was the most efﬁcient of the mole-
cules tested for inducing CXCL10 expression in VSMCs [34] and TNFα
was a stronger inducer of CCL5 mRNA production than IL-1β [35]. Our
ﬁndings also demonstrate that IL-1βwas the only one of the molecules
tested able to trigger the disruption of focal adhesions and actin stress
ﬁbers, leading to a cAMP-dependent transition to a stellatemorphology,
as observed in atherosclerotic lesions [14,20]. Finally, using the FRET-
based cAMP biosensor TEpacvv and a battery of pharmacological com-
pounds, we were able to link this cAMP-dependent phenomenon to
the autocrine/paracrine factor PGE2, which is released upon IL-1β stim-
ulation and the activation of PKA by the EP4 prostaglandin receptor.
The IL-1β-induced increase in intracellular [cAMP] mediated by the
release of the autocrine/paracrine factor PGE2 is consistent with i) the
time lag (12 h) observed between the start of IL-1β-treatment and the
development of a cAMP-dependent stellate cell morphology; and ii)
our previous results showing that PGE2 acts in synergy with IL-1β to
enhance the phenotypic transition in smooth muscle cells [22]. It is
also consistent with published data showing that the IL-1β-mediated
increase in cAMP concentration in VSMCs is due to the ability of IL-1β
to trigger prostaglandin release [25,36].
Consistent with many other studies showing that EP4 activation
leads to an increase in intracellular [cAMP] [37], we showed, by succes-
sively blocking each of the EP receptors expressed in VSMCs, that the
Gs-coupled EP receptor subtype 4 was involved in the increase in
cAMP concentration and the transition to a stellate cellmorphology. Fol-
lowing the addition of PGE2 in conditions of EP receptor subtype 3
blockade, we observed a slight (but non-signiﬁcant) decrease in cAMP
production (Fig. 6B), leading the generation of fewer stellate VSMCs
(Fig. 6F, panels PGE2 vs. PGE2 + L-798, 106). This ﬁnding is consistent
with our previous report showing that, in IL-1β-treated cells, the
PGE2-dependent increase in cAMP concentration results from activation
of the EP4 and EP3 receptors [22]. Indeed, transdifferentiation is associ-
ated with a change in the regulation (negative to positive) of the Gi-
coupled receptor EP3, potentiating the cAMP produced by Gs-coupled
EP4 receptors. One reasons for the lack of signiﬁcant results for the
EP3 antagonist is that monitoring the dynamics of cAMP productionby FRET requires the removal of IL-1β from the culture medium 24 h
before the experiment. The VSMCs transdifferentiating in response to
IL-1β may, therefore display partial reversion towards a quiescent
phenotype, accounting for the small contribution of EP3 to the PGE2-
induced increase in cAMP levels and changes in morphology.
Using the 6BNZ-cAMP (a PKA activator), a siRNA directed against the
most abundant PKA regulatory subunit, R1α, and 8-pCPT-O-Me-cAMP
(an Epac activator), we demonstrated the speciﬁc involvement of PKA
in the cAMP-dependent transition towards a stellate cell phenomenon.
However according to Hewer et al. (2011), this transition towards a stel-
late phenotype in VSMCs results from a synergic activation of PKA and
Epac not involving the Epac-dependent Rap1 protein [38]. Several studies
have reported Rap1-independent effects of Epac [39,40], but Epac activa-
tion generally leads to a Rap1-mediated GDP/GTP exchange [41]. Further-
more, Hewer et al., reported, for 8-pCPT-O-Me-cAMP, a trend towards
increasing levels of focal adhesion, a result conﬂicting with the effects of
8-pCPT-O-Me-cAMP on stellate cell morphology that they report. Thus,
for the conclusive implication or exclusion of a role for Epac in this pro-
cess, further evaluations are required of the possible activation of other
downstream Epac effectors, such as the Rit small GTPase or the c-June
N-terminal kinase, in response to PGE2 treatment.
As mentioned above, the disruption of PKAR1α in vivo is associated
with an increase in the catalytic activity of PKA [30–32], and this
increase in catalytic activity (which is lethal in the embryo due to the
failure to establish mesoderm-derived structures) is partially rescued
by eliminating the PKA catalytic subunit α [42], providing evidence
for a causal relationship between the elimination of PKAR1α and the in-
crease in PKA catalytic activity. Embryonic ﬁbroblasts from PKAR1α−/−
mouse embryos display similar changes in morphology to VSMCs in
which R1α is silenced, with a decrease in activated Rac levels [32].
Moreover, the transition of VSMCs to a stellate morphology induced
by agents increasing cAMP levels, such as isoproterenol and forskolin,
can be prevented by the expression of an activated form of Rac1. Con-
versely, the pharmacological inhibition of Rac1 or the expression of a
dominant negative form of Rac1 is sufﬁcient to induce the transition
to a stellate phenotype [20]. Finally, PKAR1α disruption in Schwann
cells is associated with a decrease in the formation of lamellopodia
[31], a process involving Rac1 activation [43]. This suggests a role for
Rac1 in the PGE2/cAMP-dependent development of stellatemorphology
in VSMCs. Furthermore, as PKA phosphorylates key actors involved in
cytoskeletal regulation, such as the vasodilator-stimulated phosphopro-
tein (VASP) [18], Ras homolog gene family member A (RhoA) [44] and
LIM domain kinase 1 (LIMK1) [32], these proteins may also be involved
in the cAMP-dependent transition to a stellate phenotype. In any event,
PKA enhances this process by phosphorylating globular actin (G-actin),
thereby decreasing ﬁlamentous actin (F-actin) formation [44]. Indeed,
PKAR1α silencing induced a destabilization of ﬁlamentous actin and
the disassembly of focal adhesions (Fig. 7C).
IL-1β-dependent transdifferentiation is associated with an increase
in PKAR1β gene expression. Nevertheless, the silencing of this subunit
does not prevent VSMCs from undergoing the transition to a stellate
phenotype following stimulation with PGE2 (Fig. 7B). We therefore
conclude that PKAR1β is not required for this process.
PKA containing PKAR1β subunits has been shown to be activated at
cAMP concentrations lower, by a factor of three to seven, than those ac-
tivating PKAR1α [45]. Therefore PKA-dependent responses should be
evenmore sensitive to any increase in intracellular cAMP concentration
in VSMCs undergoing transdifferentiation in response to IL-1β. Interest-
ingly, in PKAR1β-knockout mice, inﬂammation and nociceptive pain
levels are low in a model of paw edema and pain behavior induced by
formalin injection [46]. In addition, patientswith systemic lupus erythe-
matosus present a downregulation of PKAR1β expression and lower
levels of IL-2 secretion by T lymphocytes, these deﬁcits possibly being
rescued by PKAR1β gene transfer [47]. The data presented here are con-
sistent with a role for PKAR1β in the increase in cAMP concentration
mediating VSMC inﬂammation and, possibly, PGE2 secretion.
Fig. 7.Role of PKA in the development of a stellatemorphology in VSMCs. Phase-contrast microscopy of naive (A) and IL-1β-transdifferentiated (B) VSMCs in the presence of vehicle, Epac
(8-pCPT-O-Me-cAMP, 100 μM)and/or PKA (6BNZ-cAMP, 100 μM)activators. The concentrations used for each compound are indicated on the ﬁgure. The results shown are representative
of at least 3 independent experiments. C. Numbers of copies of PKA regulatory and catalytic subunit mRNAs in VSMCs treated with vehicle or IL-1β (5 ng/ml) for 48 h. The data shown are
themeans±SEMof at least 4 independent experiments. *, P b 0.05, ***,P b 0.001 versus vehicle-treated cells inKruskal–Wallis tests followedbyDunn'smultiple comparison test. D. Phase-
contrast microscopy of VSMCs transfected with control siRNA (siCTRL) or siRNA directed against the PKAR1α (siR1α) or PKAR1β (siR1β) subunits. Upper and lower panels: vehicle- and
PGE2−treated cells (50 nM for 1 h), respectively.
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VSMC transdifferentiation in response to exposure to pro-
atherogenic stimuli, such as the cytokines IL-1β, TNFα and IFNγ, is a
key event in the initiation and further development of atherosclerosis.
We demonstrate here that IL-1β contributes to this transdifferentiation
process not only by decreasing the expression of contractile markers,
but also by disrupting F-actin and focal adhesions through the release
of PGE2 and subsequent cAMPpathway activation. Given these andpub-
lished ﬁndings, it will be of interest to investigate the effect on plaque
development of VSMC-directed PKAR1α and/or PKAR1β gene knockout
in atherosclerosis-susceptible mouse models. Indeed, such studies
should deﬁne the roles of thesemolecules in the onset of atherosclerosis
and their potential relevance as treatment targets. Studies on human
atherothrombotic plaques should provide insight into the relationship
between PKAR1α and/or PKAR1β expression and vulnerability to
plaque formation. They should also provide a more general view of
the role of this relationship in human atherosclerosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.09.019.Acknowledgments
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